Oxygen Pulse and Its Curve Patterns in Male Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With and in Healthy Men

Sponsor
Chung Shan Medical University (Other)
Overall Status
Completed
CT.gov ID
NCT05189301
Collaborator
(none)
90
1
28.8
3.1

Study Details

Study Description

Brief Summary

Background: In non-invasive cardiopulmonary exercise testing (CPET), oxygen pulse (O2P) is defined as oxygen uptake divided by heart rate and is equal to the product of stroke volume and oxygen extraction by cells. As per, the O2P indicates the capability of oxygen consumption of whole body tissues and cells per heart beat. During exercise, the O2P changes can be deemed as the stroke volume changes as the oxygen extraction by muscle cells are normal. Hence, CPET-O2P can be non-invasively and continuously used to monitor the stroke volume changes during exercise. O2P value (i.e., % of predicted) is related to the severity and prognosis of heart failure and to the severity of constraint of the heart caused by exercise-induced hyperinflation or air trapping in patients with chronic obstructive pulmonary disease (COPD). However, O2P plateau pattern is not uncommonly encountered in the daily practice.

Hypothesis and aims: O2P patterns during incremental exercise are seldom investigated although they have been hypothesized that the plateau or decreasing patterns are related to myocardial failure or ischemia. In this proposal, the O2P patterns are to be thoroughly investigated: (1) the patterns in norms, patients with heart failure and COPD, (2) the relationship between the O2P pattern and cardiac function and/or myocardial ischemia in patients with heart failure and COPD. As yet there are no relative reports on the O2P pattern and its possible mechanisms in the literature, the results of the proposal might tremendously impact the interpretation strategy of CPET reports.

Methods: Multidisciplinary, prospective, comparative cross-sectional study is designed. Subjects aged from 40-85 years with the BMI of 18-28kg/m2 are to be enrolled: sample sizes of the norms, heart failure and COPD groups are 10, 20, and 20, respectively, equally distributed in two years. The definitions of COPD and heart failure with NYHA class I-III are according to the GOLD and ESC guidelines, respectively。All the three groups undergo CPET-NIRS, echocardiography, and the first pass and myocardial perfusion studies using Tc-99. The primary measurements are the O2P patterns and the cardiac function measured with echocardiography, the first pass and myocardial perfusion studies and air trapping in the lungs.。 Statistical analysis: For normal continuous data, t-test or ANOVA is used. For non-normal data, the Mann-Whitney test is used. The chi-square test or Fisher's exact test is used to compare the proportion of categorical variables between the two groups. A p value of less than .05 is considered to be statistically significant. Statistical procedures are performed using the SAS software package version 9.3.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: first pass study
  • Diagnostic Test: cardiopulmonary exercise testing

Study Design

Study Type:
Observational
Actual Enrollment :
90 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Differences in Oxygen Pulse Pattern During Maximum Incremental Exercise Test Between Norms and Patients With Chronic Obstructive Pulmonary Disease and With Chronic Heart Failure - the Possible Mechanisms
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
May 27, 2021

Arms and Interventions

Arm Intervention/Treatment
CHF

CHF for chronic heart failure

Diagnostic Test: first pass study
Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Diagnostic Test: cardiopulmonary exercise testing
to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)

COPD

COPD for chronic obstructive pulmonary disease

Diagnostic Test: first pass study
Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Diagnostic Test: cardiopulmonary exercise testing
to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)

control

control for normal controls

Diagnostic Test: first pass study
Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)

Diagnostic Test: cardiopulmonary exercise testing
to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)

Outcome Measures

Primary Outcome Measures

  1. O2P and its patterns [one hour]

    O2P value and its pattern were measured by exercise gas exchange.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Subjects aged from 40-85 years with the BMI of 18-28kg/m2 are to be enrolled: sample sizes of the norms, heart failure and COPD groups are 10, 20, and 20, respectively, equally distributed in two years. All of the participants had been in a stable clinical condition for at least 1 month before participating in the study. None of the participants had contraindications for cardiopulmonary exercise tests (CPETs).
Exclusion Criteria:
  • Participants with diabetes mellitus, uncontrolled hypertension, arrhythmia, cancer, liver, renal or autoimmune diseases, or anemia were excluded. However, participants with well controlled diabetes mellitus were included in the HFrEF/HFmrEF group as these conditions often co-exist. Physical activity was not encouraged or limited during the study period.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chung Shan Medical University Hospital Taichung Taiwan

Sponsors and Collaborators

  • Chung Shan Medical University

Investigators

  • Principal Investigator: Ming-Lung Chuang, M.D., Chung Shan Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ming-Lung Chuang, Visiting physician, Chung Shan Medical University
ClinicalTrials.gov Identifier:
NCT05189301
Other Study ID Numbers:
  • CSH-2019-C-030
First Posted:
Jan 12, 2022
Last Update Posted:
Jan 12, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ming-Lung Chuang, Visiting physician, Chung Shan Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 12, 2022